This article is more than 5 years old. Information may no longer be current.

Eylea recommended for approval in Europe for DME visual impairment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aflibercept injection has been recommended for approval by the European Committee for Medicinal Products for Human Use for the treatment of visual impairment due to diabetic macular edema, according to a Regeneron press release.

The recommendation is based on positive data from the phase 3 VIVID-DME and VISTA-DME studies.

“Diabetes is a growing health concern worldwide, and this milestone brings us one step closer to being able to offer patients and physicians in the European Union a new therapeutic option for the treatment of diabetic macular edema,” George D. Yancopoulos, MD, PhD, chief scientific officer of Regeneron and president of Regeneron Laboratories, said in the press release.

Two-year data from the VIVID-DME trial are expected later in 2014.

Aflibercept (Eylea) was approved in the United States for the treatment of wet age-related macular degeneration in November 2011 and for macular edema following central retinal vein occlusion (CRVO) in September 2012. It has also been approved in the European Union and in other countries for the treatment of wet AMD and macular edema following CRVO, according to the release.

The European Commission’s final decision is expected in the second half of 2014.